Just 16% Of Indian Population Has Access To Free Or Partially-Free Health Care?

Is health care currently a low priority area for the Government of India? Probably yes, and thus it is worth trying to fathom it out. Besides planned frugal spending on overall public health in 2015-16, even as compared to the past … Continue reading

“Make in India…Sell Anywhere in The World”: An Indian Pharma Perspective

In his Independent Day speech from the ramparts of the Red Fort on August 15, 2014, Indian Prime Minister Modi gave a clarion call to all investors of the world, “Come, make in India”, “Come, manufacture in India”, “Sell in … Continue reading

Union Budget 2014-15: Ticks The ‘Top Priority’ Boxes on Healthcare

The Union Budget 2014-15, especially for healthcare, needs to be analyzed against the backdrop of what the common patients have been going through in the healthcare space of India, over a period of time. In that context, I would quote … Continue reading

Discretionary ‘Non-Compete Clause’ in Pharma FDI: An Intriguing Decision

As I had commented before, the MNC investors, while acquiring controlling stake in the Indian pharmaceutical companies, henceforth, would not be generally allowed to include any ‘non-compete clause’ in their agreement with the Indian promoters. However, this clause may be … Continue reading

Sets 2013, Dawns 2014: Top 7 Pharma Developments

Wish You Good Health, Happiness, Success and Prosperity in 2014 In this article I shall focus on ‘Top 7 Pharma Developments’, both while ‘Looking Back to 2013′ and also during my ‘Crystal Gazing 2014′. Looking Back to 2013: While looking … Continue reading

Pharma FDI Debate: Highly Opinionated, Sans Assessment of Tangible Outcomes?

In 2001, the Government of India (GoI) allowed 100 percent Foreign Direct Investments (FDI) in the pharmaceutical sector through automatic route to attract more investments for new asset creation, boost R&D, new job creation and ultimately to help aligning Indian … Continue reading

Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes…and Avoids Ruffling Feathers?

An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department … Continue reading

Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either

The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter … Continue reading